Want to see IN:TATVA full AI Analyst Report?
TATVA Stock Chart & Stats
₹1388.35
-₹14.30(-1.60%)
At close: 4:00 PM EST
₹1388.35
-₹14.30(-1.60%)
Day’s Range― - ―
52-Week Range₹977.85 - ₹1,786.70
Previous CloseN/A
Volume13.99K
Average Volume (3M)12.52K
Market Cap
₹40.10B
Enterprise Value₹25.70K
Total Cash (Recent Filing)₹87.91M
Total Debt (Recent Filing)₹1.20B
Price to Earnings (P/E)95.3
Beta1.13
Next Earnings
Oct 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.06%
Share Statistics
EPS (TTM)17.98
Shares Outstanding23,392,056
10 Day Avg. Volume25,333
30 Day Avg. Volume12,516
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.15
Price to Sales (P/S)4.87
P/FCF Ratio-29.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)29.75
Revenue Forecast (FY)₹6.27B
Bulls Say, Bears Say
Bulls Say
Product Portfolio & End‑Market DiversityTatva Chintan's mix of phase transfer catalysts, battery electrolyte salts and pharma/agro intermediates spreads demand across pharma, agro and energy-storage end markets. This diversified specialty portfolio supports recurring, higher-value sales and reduces reliance on any single cyclical sector over months.
Conservative Balance SheetA strong equity cushion and modest net debt provide financial flexibility to absorb working‑capital swings or fund capex without immediate refinancing pressure. Improved leverage versus prior years reduces solvency risk and supports multi‑month resilience as earnings recover.
Recent Revenue Recovery / Growth TrajectoryThe FY2026 revenue rebound signals reaccelerating demand and the potential to leverage fixed costs. Sustained top‑line growth over several quarters can translate into steadier margins and better cash conversion if management sustains pricing and customer traction across key product lines.
Bears Say
Weak Free Cash FlowPersistent negative free cash flow forces dependence on internal reserves or external financing to fund operations and growth. Until cash conversion improves, the company faces constrained ability to self‑fund capex, pay dividends, or reduce leverage, raising execution risk over months.
Volatile ProfitabilityLarge swings in operating profit reflect inconsistent cost pass‑through or product‑mix pressures. Continued earnings volatility undermines predictability of margins and returns, complicating planning and investor confidence until profitability stabilizes across cycles.
Rising Debt Step‑Up RiskAn uptick in leverage after prior reductions increases refinancing and servicing risk if operating cash flow lags. If return on invested capital doesn't improve, higher debt could limit strategic flexibility and pressure margins through higher interest costs over the medium term.
Tatva Chintan Pharma Chem Limited News
TATVA FAQ
What was Tatva Chintan Pharma Chem Limited’s price range in the past 12 months?
Tatva Chintan Pharma Chem Limited lowest stock price was ₹977.85 and its highest was ₹1786.70 in the past 12 months.
What is Tatva Chintan Pharma Chem Limited’s market cap?
Tatva Chintan Pharma Chem Limited’s market cap is ₹40.10B.
When is Tatva Chintan Pharma Chem Limited’s upcoming earnings report date?
Tatva Chintan Pharma Chem Limited’s upcoming earnings report date is Oct 30, 2026 which is in 100 days.
How were Tatva Chintan Pharma Chem Limited’s earnings last quarter?
Tatva Chintan Pharma Chem Limited released its earnings results on Jul 17, 2026. The company reported ₹7 earnings per share for the quarter, beating the consensus estimate of ₹6.05 by ₹0.95.
Is Tatva Chintan Pharma Chem Limited overvalued?
According to Wall Street analysts Tatva Chintan Pharma Chem Limited’s price is currently Overvalued.
Does Tatva Chintan Pharma Chem Limited pay dividends?
Tatva Chintan Pharma Chem Limited pays a Annually dividend of ₹1 which represents an annual dividend yield of 0.06%. See more information on Tatva Chintan Pharma Chem Limited dividends here
What is Tatva Chintan Pharma Chem Limited’s EPS estimate?
Tatva Chintan Pharma Chem Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tatva Chintan Pharma Chem Limited have?
Tatva Chintan Pharma Chem Limited has 23,392,056 shares outstanding.
What happened to Tatva Chintan Pharma Chem Limited’s price movement after its last earnings report?
Tatva Chintan Pharma Chem Limited reported an EPS of ₹7 in its last earnings report, beating expectations of ₹6.05. Following the earnings report the stock price went up 0.851%.
Which hedge fund is a major shareholder of Tatva Chintan Pharma Chem Limited?
Currently, no hedge funds are holding shares in IN:TATVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tatva Chintan Pharma Chem Limited
Tatva Chintan Pharma Chem Limited, an Indian-based enterprise, specializes in the production and distribution of diverse specialty chemicals. Its extensive product range encompasses essential components like structure-directing agents crucial for zeolite synthesis, phase transfer catalysts, and electrolyte salts vital for supercapacitor batteries. Furthermore, the company supplies pharmaceutical active pharmaceutical ingredients (APIs), agrochemical formulations, and various other specialized chemical products, including intermediates, disinfectants, catalytic agents, and solvents. Beyond manufacturing, Tatva Chintan engages in the trading of specialty chemicals and offers quaternary compounds (quats) and bulk drug substances. The firm's clientele spans a broad spectrum of sectors, such as the automotive, petrochemical, pharmaceutical, agricultural chemicals, paints and coatings, dyes and pigments, personal care, and flavor and fragrance industries. Its global reach extends to approximately 25 nations, where its products are exported. Established in 1996, Tatva Chintan Pharma Chem Limited maintains its corporate headquarters in Vadodara, India.
Technical Analysis
AARTI Industries Ltd
―
Alkyl Amines Chemicals Limited
―
Jubilant Ingrevia Ltd.
―
Rossari Biotech Ltd
―
Vinati Organics Limited
―